{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.21","upperLimit":"0.42","value":"0.31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"description":"27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as \\>/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as \\>/=25% or \\>/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: \\< 20 kg at 100 mg; 20-50 kg at 200 mg; \\> 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).","id":"OG000","title":"5-drug Metronomic Antiangiogenic Regimen"}],"paramType":"NUMBER","populationDescription":"The analysis dataset is comprised of all treated patients.","timeFrame":"Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.","title":"27-Week Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"Probability"}